This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2014 Feb 15;20(4):1058.

doi: 10.1158/1078-0432.CCR-13-3269.

Biomarkers and response to bevacizumab--response

Fiona Collinson¹, Michelle Hutchinson, Rachel A Craven, David A Cairns, Zougman Alexandre, Tobias C Wind, Narinder Gahir, Michael P Messenger, Sharon Jackson, Douglas Thompson, Cybil Adusei, Jonathan Ledermann, Geoffrey Hall, Gordon C Jayson, Peter J Selby, Rosamonde E Banks

Affiliations

Affiliation

¹ Authors' Affiliations: Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds; St James's Institute of Oncology, Bexley Wing; Cancer Research UK Centre, Leeds Institute of Molecular Medicine, St James's University Hospital; Department of Clinical Biochemistry and Immunology, Leeds General Infirmary, Leeds; MRC Clinical Trials Unit; UCL Cancer Institute, University College, London; and Christie Hospital, University of Manchester, Withington, Manchester, United Kingdom.

PMID: 24536077
DOI: 10.1158/1078-0432.CCR-13-3269

Comment

Biomarkers and response to bevacizumab--response

Fiona Collinson et al. Clin Cancer Res. 2014.

. 2014 Feb 15;20(4):1058.

doi: 10.1158/1078-0432.CCR-13-3269.

Authors

Fiona Collinson¹, Michelle Hutchinson, Rachel A Craven, David A Cairns, Zougman Alexandre, Tobias C Wind, Narinder Gahir, Michael P Messenger, Sharon Jackson, Douglas Thompson, Cybil Adusei, Jonathan Ledermann, Geoffrey Hall, Gordon C Jayson, Peter J Selby, Rosamonde E Banks

Affiliation

¹ Authors' Affiliations: Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds; St James's Institute of Oncology, Bexley Wing; Cancer Research UK Centre, Leeds Institute of Molecular Medicine, St James's University Hospital; Department of Clinical Biochemistry and Immunology, Leeds General Infirmary, Leeds; MRC Clinical Trials Unit; UCL Cancer Institute, University College, London; and Christie Hospital, University of Manchester, Withington, Manchester, United Kingdom.

PMID: 24536077
DOI: 10.1158/1078-0432.CCR-13-3269

No abstract available

PubMed Disclaimer

Comment on

Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selection.
Collinson F, Hutchinson M, Craven RA, Cairns DA, Zougman A, Wind TC, Gahir N, Messenger MP, Jackson S, Thompson D, Adusei C, Ledermann JA, Hall G, Jayson GC, Selby PJ, Banks RE. Collinson F, et al. Clin Cancer Res. 2013 Sep 15;19(18):5227-39. doi: 10.1158/1078-0432.CCR-13-0489. Epub 2013 Aug 9. Clin Cancer Res. 2013. PMID: 23935036 Free PMC article. Clinical Trial.
Biomarkers and response to bevacizumab--letter.
Cremolini C, Loupakis F, Bocci G, Falcone A. Cremolini C, et al. Clin Cancer Res. 2014 Feb 15;20(4):1056-7. doi: 10.1158/1078-0432.CCR-13-2763. Clin Cancer Res. 2014. PMID: 24536076 No abstract available.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
- Silverchair Information Systems
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information